Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206970 | 0.93 | TLR2 (0.45) | PTPN11TLR2TLR1TLR6 | |
| SCHEMBL20206969 | 0.90 | PTPN11 (0.46) | PTPN11TLR2TLR1TLR6 | |
| SCHEMBL20206972 | 0.84 | KDM4E (0.47) | PTPN11KDM4EGAA | |
| SCHEMBL20206971 | 0.81 | HPGD (0.49) | L3MBTL1 | |
| SCHEMBL20207003 | 0.80 | PTPN11 (0.49) | PTPN11TLR2TLR1TLR6 | |
| SCHEMBL20206974 | 0.78 | TLR2 (0.45) | PTPN11TLR2TLR1TLR6 | |
| SCHEMBL20191154 | 0.78 | PTPN11 (0.71) | PTPN11L3MBTL1KDM4EGAATLR2 | |
| SCHEMBL20188864 | 0.78 | TLR2 (0.60) | PTPN11TLR2TLR1TLR6 | |
| SCHEMBL20189050 | 0.77 | PTPN11 (0.73) | PTPN11GAATLR2TLR1TLR6 | |
| SCHEMBL20187628 | 0.77 | PTPN11 (0.68) | PTPN11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544952-B1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIV ANTWERPEN (BE) | 2024-11-06 | — | — | EP | disclosed |
| US-10738002-B2 | Halogenated benzotropolones as ATG4B inhibitors | UNIVERSITAIR ZIEKENHUIS ANTWERPEN (BE) | 2020-08-11 | — | — | US | disclosed |
| US-10738002-B2 | Halogenated benzotropolones as ATG4B inhibitors | UNIVERSITAIR ZIEKENHUIS ANTWERPEN (BE) | 2020-08-11 | — | — | US | disclosed |
| EP-3544952-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | Universiteit Antwerpen (BE) | 2019-10-02 | — | — | EP | disclosed |
| US-20190284130-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284130-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2019-09-19 | — | — | US | disclosed |
| WO-2018096088-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018096088-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284130-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | ATG4B, ATG7, ATG4A | PTPN11 2700/4885L3MBTL1 1773/4885KDM4E 962/4885 |
| US-10738002-B2 | Halogenated benzotropolones as ATG4B inhibitors | ATG4B, ATG7, BECN1 | PTPN11 2737/4885L3MBTL1 2480/4885KDM4E 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.